Latest News and Press Releases

WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and...

WALTHAM, Mass., May 10, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and...

TYMLOS® U.S. net sales were $29.8 million in the first quarter of 2019 doubling over the first quarter of 2018. TYMLOS continued increasing its share in the U.S. anabolic osteoporosis market...

WALTHAM, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019. The Company...

WALTHAM, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...

-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies...

WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...

WALTHAM, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the...

WALTHAM, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global...

TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018 and totaling $99.2 million for full-year 2018, exceeding the Company’s guidance of $95-98 million. ...